arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Scholar Rock Holding Corp

SRRK
$45.48 ▼ -0.62 (-1.33%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
38 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Scholar Rock Holding Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.9B
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -19.1% ↘
FCF / Share $-0.54 ↗
Trailing P/E —
Price / Book 21.8x
FCF Yield —
Debt / Equity 0.77
info Valuation on last close. End-of-day price, Nov 5, 2026.

38-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-105.51M
↓ -41.2% —
Operating Margin Operating profit as % of sales
-20.9%
↑ +95.8% —
FCF / Share Free cash flow per share
$-0.54
↑ +16.6% —
Long-Term Debt Long-term obligations
$196.20M
— -0.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
4
Financial Health ↑
36
Cash Quality ↓
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 38 quarters